Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira BioSciences, Inc. (PCRX) Q4 2024 Earnings Call Transcript
09:04pm, Thursday, 27'th Feb 2025
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer S
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal sec
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
07:30pm, Thursday, 27'th Feb 2025
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare
Pacira (PCRX) Tops Q4 Earnings Estimates
07:25pm, Thursday, 27'th Feb 2025
Pacira (PCRX) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.89 per share a year ago.
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
06:00pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal sec
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences,
Shareholders That Lost Money on Pacira BioSciences, Inc. (PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
04:15pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal sec
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
04:05pm, Thursday, 27'th Feb 2025
— Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J.
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
04:00pm, Thursday, 27'th Feb 2025
-- Advances Pacira's “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local-delivery platform for the development of genetic medicines with dis
PCRX Deadline: PCRX Investors with Losses in Excess of $100K Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
03:54pm, Thursday, 27'th Feb 2025
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and Augus
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX
12:45pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal sec
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)
12:38pm, Thursday, 27'th Feb 2025
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.
NEW ORLEANS, Feb. 27, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a secur
Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
10:45am, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal sec
